Lucia Lapenna

Dr. Lucia Lapenna

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Journal of Hepatology
Verified
Journal Article
Open access
Simone Di ColaSimone Di Cola
Simone Di Cola
GDGennaro D’AMico
Gennaro D’AMico
PCPaolo Caraceni
Paolo Caraceni
FSFilippo Schepis
Filippo Schepis
SLSimone Loredana
Simone Loredana
LVLuca Vizioli
Luca Vizioli
Sarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over a 12-month period. We conducted a prospective multicentre study involving 433 patients. Sarcopenia and myosteatosis were evaluated using computed tomography scans. The 1-year cumulative incidence of relevant events was assessed by competing risk analysis. We used a Fine-Gray model adjusted for known prognostic factors, to evaluate the impact of sarcopenia and myosteatosis on mortality, hospitalization, and liver decompensation. At enrolment, 166 patients presented with isolated myosteatosis, 36 with isolated sarcopenia, 135 with combined sarcopenia and myosteatosis and 96 patients showed no muscle changes. The 1-year cumulative incidence of death in patients with either sarcopenia and myosteatosis (13.8%) or isolated myosteatosis (13.4%) was over twice that of patients without muscle changes (5.2%) or with isolated sarcopenia (5.6%). The adjusted subhazard ratio for death in patients with muscle changes was 1.36 (95% CI 0.99, 1.86) (P=0.058). The cumulative incidence of hospitalization was significantly higher in patients with combined sarcopenia and myosteatosis than in patients without muscle changes (adjusted subhazard ratio 1.18, 95% CI 1.04 to 1.35). The cumulative incidence of liver decompensation was greater in patients with combined sarcopenia and myosteatosis (p=0.018) and those with isolated sarcopenia (p=0.046) than in patients without muscle changes. Lastly, we found a strong correlation between function tests and frailty scores with the presence of muscle changes. Myosteatosis, whether alone or combined with sarcopenia, is highly prevalent in patients with cirrhosis and is associated with significantly worse outcomes. The prognostic role of sarcopenia should always be evaluated in relation to the presence of myosteatosis. This study investigates the prognostic role of muscle changes in patients with liver cirrhosis. The novelty of this study is the multicentre, prospective nature and the distinguishing impact of individual muscle changes and their combination on prognosis in cirrhosis. This study highlights the prognostic role of myosteatosis, especially when combined with sarcopenia. On the other hand, the relevance of sarcopenia could be mitigated when considered together with myosteatosis. The implication from these findings is that sarcopenia should never be evaluated individually and that myosteatosis may have a dominant role in the prognosis of patients with liver cirrhosis.

27 March 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
JGJakub Gazda
Jakub Gazda
Simone Di ColaSimone Di Cola
Simone Di Cola
LLLucia Lapenna
Lucia Lapenna
SKSaniya Khan
Saniya Khan
Manuela MerliManuela Merli
Manuela Merli
Background and Aims: Liver cirrhosis leads to clinically significant portal hypertension. Transjugular intrahepatic portosystemic shunt (TIPS) has been shown to effectively reduce the degree of portal hypertension and treat its complications. However, poor nutritional status has been shown to be associated with hepatic encephalopathy, acute on chronic liver failure, and mortality following TIPS placement. The purpose of this systematic review is to create another perspective and evaluate the effect of TIPS placement on the nutritional status of patients with liver cirrhosis. Methods: A comprehensive search of four major electronic databases was conducted to identify studies that assessed the nutritional status of cirrhotic patients before and after TIPS placement. The risk of bias was evaluated using ROBINS-I guidelines. Results: Fifteen studies were analyzed in this review. The results indicate that among the 11 studies that evaluated changes in ascites-free weight and body mass index or body cell mass, 10 reported an improvement in one or more measures. Furthermore, all seven studies that evaluated changes in muscle mass demonstrated an increase in muscle mass. Among the four studies that evaluated subcutaneous fat tissue, three showed a significant expansion, while two out of three studies evaluating visceral fat tissue reported a significant reduction. Conclusions: The results of this systematic review suggest that TIPS placement is associated with improvement in the nutritional status of cirrhotic patients, indicated by an increase in ascites-free weight, body mass index, and muscle mass. Additionally, TIPS placement leads to a shift in the distribution of fat mass, with a preference for subcutaneous over visceral adipose tissue. Notably, sarcopenic patients seem to benefit the most from TIPS placement in terms of nutritional status.

9 February 2023 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Open access
LLLucia Lapenna
Lucia Lapenna
Simone Di ColaSimone Di Cola
Simone Di Cola
JGJakub Gazda
Jakub Gazda
IFIlaria De Felice
Ilaria De Felice
SGStefania Gioia
Stefania Gioia
Manuela MerliManuela Merli
Manuela Merli
Since 1988, transjugular intrahepatic portosystemic shunt (TIPS) has been an effective therapy for portal hypertension in many settings. Thanks to continuous technical improvements and a wiser selection of patients, excellent results have been achieved with this therapeutic strategy. The historical indications for TIPS placement, in the context of liver cirrhosis, such as refractory ascites and variceal bleeding are now well established and known. However, in recent years, new indications are emerging. These have been investigated and approved in some studies but are not yet included in guidelines and clinical practice. This review aims to highlight what is new for the role of TIPS in portal vein thrombosis (especially in patients awaiting liver transplantation), in recurrent ascites and not only refractory ascites, as a neoadjuvant therapy before abdominal surgery and, finally, in the setting of noncirrhotic portal hypertension. All these new aspects are addressed in this review with a critical approach based on the literature revision and clinical practice. Future research is needed to explore and validate the new role of TIPS in these scenarios.

20 February 2023 in JHEP Reports
Verified
Journal Article
Open access
Simone Di ColaSimone Di Cola
Simone Di Cola
JGJakub Gazda
Jakub Gazda
LLLucia Lapenna
Lucia Lapenna
GCGiancarlo Ceccarelli
Giancarlo Ceccarelli
Manuela MerliManuela Merli
Manuela Merli
Bacterial infections affect survival of patients with cirrhosis. Hospital-acquired bacterial infections present a growing healthcare problem because of the increasing prevalence of multidrug-resistant organisms. This study aimed to investigate the impact of an infection prevention and control programme and coronavirus disease 2019 (COVID-19) measures on the incidence of hospital-acquired infections and a set of secondary outcomes, including the prevalence of multidrug-resistant organisms, empiric antibiotic treatment failure, and development of septic states in patients with cirrhosis. The infection prevention and control programme was a complex strategy based on antimicrobial stewardship and the reduction of patient's exposure to risk factors. The COVID-19 measures presented further behavioural and hygiene restrictions imposed by the Hospital and Health Italian Sanitary System recommendations. We performed a combined retrospective and prospective study in which we compared the impact of extra measures against the hospital standard. We analysed data from 941 patients. The infection prevention and control programme was associated with a reduction in the incidence of hospital-acquired infections (17 vs. 8.9%, p <0.01). No further reduction was present after the COVID-19 measures had been imposed. The impact of the infection prevention and control programme remained significant even after controlling for the effects of confounding variables (odds ratio 0.44, 95% CI 0.26-0.73, p = 0.002). Furthermore, the adoption of the programme reduced the prevalence of multidrug-resistant organisms and decreased rates of empiric antibiotic treatment failure and the development of septic states. The infection prevention and control programme decreased the incidence of hospital-acquired infections by nearly 50%. Furthermore, the programme also reduced the prevalence of most of the secondary outcomes. Based on the results of this study, we encourage other liver centres to adopt infection prevention and control programmes. Infections are a life-threatening problem for patients with liver cirrhosis. Moreover, hospital-acquired infections are even more alarming owing to the high prevalence of multidrug-resistant bacteria. This study analysed a large cohort of hospitalised patients with cirrhosis from three different periods. Unlike in the first period, an infection prevention programme was applied in the second period, reducing the number of hospital-acquired infections and containing multidrug-resistant bacteria. In the third period, we imposed even more stringent measures to minimise the impact of the COVID-19 outbreak. However, these measures did not result in a further reduction in hospital-acquired infections.

21 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Simone Di ColaSimone Di Cola
Simone Di Cola
LLLucia Lapenna
Lucia Lapenna
JGJakub Gazda
Jakub Gazda
SFStefano Fonte
Stefano Fonte
GCGiulia Cusi
Giulia Cusi
Manuela MerliManuela Merli
Manuela Merli
Liver transplantation is currently the only curative therapy for patients with liver cirrhosis. Not all patients in the natural course of the disease will undergo transplantation, but the majority of them will experience portal hypertension and its complications. In addition to medical and endoscopic therapy, a key role in managing these complications is played by the placement of a transjugular intrahepatic portosystemic shunt (TIPS). Some indications for TIPS placement are well-established, and they are expanding and broadening over time. This review aims to describe the role of TIPS in managing patients with liver cirrhosis, in light of liver transplantation. As far as it is known, TIPS placement seems not to affect the surgical aspects of liver transplantation, in terms of intraoperative bleeding rates, postoperative complications, or length of stay in the Intensive Care Unit. However, the placement of a TIPS “towards transplant” can offer advantages in terms of ameliorating a patient’s clinical condition at the time of transplantation and improving patient survival. Additionally, the TIPS procedure can help preserve the technical feasibility of the transplant itself. In this context, indications for TIPS placement at an earlier stage are drawing particular attention. However, TIPS insertion in decompensated patients can also lead to serious adverse events. For these reasons, further studies are needed to make reliable recommendations for TIPS in the pre-transplant setting.

7 March 2025 in JHEP Reports
Verified
Journal Article
Open access
CBChiara Becchetti
Chiara Becchetti
STSilvia Trapani
Silvia Trapani
LMLucia Masiero
Lucia Masiero
STSilvia Testa
Silvia Testa
FDFrancesca D'Arcangelo
Francesca D'Arcangelo
PBPatrizia Burra
Patrizia Burra
Although sex-based disparities in the liver transplantation (LT) setting have been acknowledged for several years, particularly by studies conducted in the USA, data from European countries are scarce. We conducted a nationwide, retrospective, observational study on candidates identified for LT in Italy between January 2017 and December 2021 using national registry data with follow-up until June 2023. The primary aim was to assess sex-based differences in LT access, analyzing delisting, retransplantation, and mortality rates. Patients were monitored from waitlist admission to transplant, removal, or death, with competing risks modeled (Fine and Gray) multivariable analysis. Survival outcomes were evaluated using Kaplan–Meier estimates, time-dependent Cox models, and stratified log-rank tests. In total, 7,563 patients were included in the analysis, 5,575 (73.7%) of whom were men. Men had higher 1- and 2-year probabilities of undergoing LT compared with women for both liver cirrhosis (subdistribution hazard ratio [sHR] 1.13, 95% CI 1.02–1.26, p = 0.02 and sHR 1.12, 95% CI 1.01–1.24, p = 0.03, respectively) and hepatocellular carcinoma (HCC) (sHR 1.20, 95% CI 1.07–1.36, p = 0.003 and sHR 1.21, 95% CI 1.08–1.35, p = 0.001, respectively). The wait list (WL) dropout rate in men did not differ significantly to that for women (12.6% vs. 13.9%, p = 0.14) except when the indication to LT was HCC (10.6% vs. 14.2%, p = 0.035). In addition, men had a lower wait list (WL) mortality rate compared with women (7.0% vs. 8.5%, p = 0.04). Post-LT survival rates were similar for both sexes. In this large Italian cohort, female standard allocation patients appeared to be at a disadvantage compared with men, because they received LT less frequently, but with similar post-LT outcomes. Although sex-based disparities in the LT setting have been acknowledged for several years, particularly in studies conducted in the USA, few data are available in Europe. Our study provides an exhaustive overview regarding the disadvantage facing women outside the USA in accessing LT. By detailing these differences, it provides solid arguments for developing equitable health policy. Given that these differences are affected by the national scenario, having local data is crucial for defining possible targeted actions.